GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evofem Biosciences Inc (OTCPK:EVFM) » Definitions » Cyclically Adjusted Price-to-FCF

Evofem Biosciences (Evofem Biosciences) Cyclically Adjusted Price-to-FCF : (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Evofem Biosciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Evofem Biosciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Evofem Biosciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evofem Biosciences Cyclically Adjusted Price-to-FCF Chart

Evofem Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Evofem Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Evofem Biosciences's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Evofem Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evofem Biosciences's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's Cyclically Adjusted Price-to-FCF falls into.



Evofem Biosciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Evofem Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Evofem Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.008/129.4194*129.4194
=-0.008

Current CPI (Dec. 2023) = 129.4194.

Evofem Biosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -2,786.000 99.695 -3,616.673
201406 -1,913.000 100.560 -2,462.018
201409 -1,732.000 100.428 -2,231.996
201412 -3,160.000 99.070 -4,128.056
201503 -5,029.000 99.621 -6,533.256
201506 -7,804.000 100.684 -10,031.286
201509 -11,729.000 100.392 -15,120.405
201512 -13,576.000 99.792 -17,606.529
201603 -7,606.000 100.470 -9,797.552
201606 -2,637.000 101.688 -3,356.135
201609 -3,123.000 101.861 -3,967.925
201612 -2,889.000 101.863 -3,670.555
201703 -6,069.000 102.862 -7,635.908
201706 -3,473.000 103.349 -4,349.081
201709 -4,751.000 104.136 -5,904.528
201712 -4,949.000 104.011 -6,157.964
201803 -2,267.250 105.290 -2,786.851
201806 -1,744.273 106.317 -2,123.303
201809 -637.714 106.507 -774.905
201812 -731.929 105.998 -893.657
201903 -548.429 107.251 -661.790
201906 -977.400 108.070 -1,170.492
201909 -577.000 108.329 -689.333
201912 -498.000 108.420 -594.455
202003 -575.808 108.902 -684.295
202006 -499.774 108.767 -594.668
202009 -839.977 109.815 -989.932
202012 -941.860 109.897 -1,109.177
202103 -804.864 111.754 -932.089
202106 -819.552 114.631 -925.278
202109 -462.976 115.734 -517.721
202112 -247.884 117.630 -272.729
202203 -235.787 121.301 -251.568
202206 -123.641 125.017 -127.995
202209 -3.685 125.227 -3.808
202212 -6.666 125.222 -6.889
202303 -3.886 127.348 -3.949
202306 -0.949 128.729 -0.954
202309 -0.003 129.860 -0.003
202312 -0.008 129.419 -0.008

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evofem Biosciences  (OTCPK:EVFM) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Evofem Biosciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Evofem Biosciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Evofem Biosciences (Evofem Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Executives
Yan Zhang officer: Chief Financial Officer 6166 TIKI CT, SAN DIEGO CA 92130
Kim P. Kamdar director, 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Jenny C. Yip director 12400 HIGH BLUFF DR., STE. 600, SAN DIEGO CA 92130
Atkinson Katherine Cocca officer: Chief Commercial Officer 12400 HIGH BLUFF., STE. 600, SAN DIEGO CA 92130
Saundra L Pelletier director, officer: Chief Executive Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Alexander A Fitzpatrick officer: General Counsel and Secretary 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Justin J. File officer: Chief Financial Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Anthony Stephen O'brien director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Russell Barrans officer: Chief Commercial Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Dale Rarick director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, STE 600, SAN DIEGO CA 92130
William Walmsley Hall director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DIRVE, SUITE 600, SAN DIEGO CA 92130
Invesco Ltd. 10 percent owner 1331 SPRING STREET NW, SUITE 2500, ATLANTA GA 30309
Link Fund Solutions Ltd 10 percent owner 65 GRESHAM STREET, LONDON X0 EC2V 7NQ
Acacia Research Corp 10 percent owner 767 3RD AVENUE, 6TH FLOOR, NEW YORK NY 10017
Kelly Culwell officer: Chief Medical Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130